Amylyx Pharmaceuticals, Inc.

AMLX

$30.61

Updated: 24/09/2026, 08:03:05

Market Cap

$3.40B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for AMLX

Company Profile

Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.

USD

NASDAQ

CEO: Joshua Cohen

Employees: 136

https://amylyx.com

Asset Summaries

Latest generated summaries for AMLX

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for AMLX.

Share price: $30.61
Market cap: $3.40B
Exchange: NASDAQ
Currency: USD
CEO: Joshua Cohen
Employees: 136
IPO date: 07/01/2022
Beta: -0.205
Last dividend: $0.00
Day range: $30.54 – $32.98
52-week range: $10.83 – $41.14
1-day performance: -7.26%
1-year performance: 182.59%
Current drawdown (1Y): -25.61%
CIK: 0001658551
CUSIP: 03237H101
ISIN: US03237H1014
Created: 07/12/2025, 02:03:40
Last update: 24/09/2026, 08:03:05

Track Amylyx Pharmaceuticals, Inc. with an AI analyst

See which prediction-market events move AMLX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to AMLX from your Railway `news_articles` table.

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 10/06/2026, 15:52:16

Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus

MarketBeat • STOCK • 14/05/2026, 03:06:33

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 13/05/2026, 22:20:47

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 07/05/2026, 19:01:47

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

PRNewsWire • STOCK • 09/04/2026, 21:54:00

Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point

Seeking Alpha • STOCK • 04/03/2026, 19:03:30

Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2025 Earnings Call Transcript

Seeking Alpha • STOCK • 03/03/2026, 17:32:51

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Sees Rising Optimism Among Analysts

Market Data • Market Data • 02/03/2026, 22:00:02

Amylyx Pharmaceuticals Co-Chief Executive Sells AMLX 138K Shares for $1.9 Million

The Motley Fool • STOCK • 01/02/2026, 00:49:44